technical note singlera · dna originates from cancer cells. while ctdna mutations (snvs, indel,...
TRANSCRIPT
SINGLERA
SINGLERA
Genomics
Early cancer detection is vital to improving patient outcomes
Circulating tumor DNA (ctDNA) as a cancer marker
Tumors or circulating tumor cells release ctDNA into the blood when undergoing apoptosis or necrosis. Approximately 0.1% to 10% of cell-free DNA originates from cancer cells. While ctDNAmutations (SNVs, indel, and CNAs) can be used as markers for cancer detection, the signals can be noisy due to molecule loss during library construction, PCR artifacts, and sequencing errors.
PanSeer reduces noise by looking for distinct tumor-specific methylation patterns in adjacent methylation sites. The ctmDNA (circulating tumor methylated DNA) technology interrogates over 12,000 methylation marker patterns. Noise is also reduced by employing a highly efficient targeted sequencing library construction method.
Blood DrawPlasma
SeparationDNA
Extraction
PanSeerAssay
1 day workflow
SequencingProprietary
Analysis
Singlera Genomics Inc.505 Coast Blvd South Ste 307, La Jolla, CA, 92037, USA Tel: 1 858 732 0061, Email: [email protected] Web: www.singlera.com
Late stage cancers often lack an effective treatment option. Five-year survival rates for certain cancers, such as colon cancer, are as high as 92% if detected in stage I; however, the survival rate drops dramatically as cancer progresses to later stages.
DETECTED EARLY DETECTED LATE
2 of 10survive 5 years
9 of 10survive 5 years
PanSeerNon-invasive early cancer detection
For research use only. Not for diagnostic purposes.
American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta: American Cancer Society; 2016
Technical Note
Post-diagnosis
89.4%161/180
Years prior to diagnosis
0-1 Year
71.0%22/31
1-2 Years
76.9%30/39
2-3 Years
74.5%35/47
3-4 Years
61.9%26/42
92.6%461/498
PanSeer can detect cancer up to 4 years prior to conventional diagnosis
PanSeer performance by covariate analysis
Singlera Genomics Inc.505 Coast Blvd South Ste 307, La Jolla, CA, 92037, USA Tel: 1 858 732 0061, Email: [email protected] Web: www.singlera.com
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 Year 11
Taizhou Longitudinal Study
Blood Sample Collection
Participant Monitoring
The Taizhou Longitudinal Study monitored the health of ~120,000 participants over the course of 2008-2018. Plasma samples were collected at the start of the study and participant health was monitored regularly over this time period. 1,379 randomly selected samples were used to train and test the PanSeer assay.
ROC for post- and pre-diagnosis samples(Star shows cutoff from training set)
Sensitivity in post-diagnosis samples by stage Sensitivity in post-diagnosis samples by tissue
~120,000Participants
PanSeer results in blinded test samples
For research use only. Not for diagnostic purposes.
Sensitivity
Specificity
Wang X. et al. (2009). Rationales, design and recruitment of the Taizhou Longitudinal Study. BMC public health, 9(1), 223.
Healthy
Technical Note